MA56019A - Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies - Google Patents
Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladiesInfo
- Publication number
- MA56019A MA56019A MA056019A MA56019A MA56019A MA 56019 A MA56019 A MA 56019A MA 056019 A MA056019 A MA 056019A MA 56019 A MA56019 A MA 56019A MA 56019 A MA56019 A MA 56019A
- Authority
- MA
- Morocco
- Prior art keywords
- diseases
- treatment
- pharmaceutical compositions
- new compounds
- related pharmaceutical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1907616.5A GB201907616D0 (en) | 2019-05-29 | 2019-05-29 | Novel compounds and pharmaceutical compositons thereof for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56019A true MA56019A (fr) | 2022-04-06 |
Family
ID=67385363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056019A MA56019A (fr) | 2019-05-29 | 2020-05-25 | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US12391679B2 (fr) |
| EP (1) | EP3976189B1 (fr) |
| JP (1) | JP7550174B2 (fr) |
| CN (1) | CN113924146B (fr) |
| AR (1) | AR119028A1 (fr) |
| AU (1) | AU2020281650B2 (fr) |
| BR (1) | BR112021023900A2 (fr) |
| CA (1) | CA3141683A1 (fr) |
| CL (1) | CL2021003133A1 (fr) |
| CO (1) | CO2021017656A2 (fr) |
| CR (1) | CR20210586A (fr) |
| DO (1) | DOP2021000227A (fr) |
| EA (1) | EA202193281A1 (fr) |
| ES (1) | ES2985528T3 (fr) |
| GB (1) | GB201907616D0 (fr) |
| IL (1) | IL288375B2 (fr) |
| MA (1) | MA56019A (fr) |
| MX (1) | MX2021013803A (fr) |
| PE (1) | PE20220503A1 (fr) |
| PH (1) | PH12021552691A1 (fr) |
| PL (1) | PL3976189T3 (fr) |
| SG (1) | SG11202112652RA (fr) |
| TW (1) | TW202110839A (fr) |
| WO (1) | WO2020239658A1 (fr) |
| ZA (1) | ZA202110597B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241435B2 (en) | 2016-09-16 | 2022-02-08 | The General Hospital Corporation | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis |
| IL312955B1 (en) | 2019-03-11 | 2026-01-01 | Inflarx Gmbh | Fused piperidinyl bicyclic compounds and related compounds as C5a receptor modulators |
| GB201907558D0 (en) * | 2019-05-29 | 2019-07-10 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| CN116234549B (zh) * | 2020-08-05 | 2025-11-25 | 总医院公司 | 盐诱导激酶抑制剂 |
| CN115197208A (zh) * | 2021-04-01 | 2022-10-18 | 江苏恒瑞医药股份有限公司 | 杂芳基类化合物、其制备方法及其在医药上的应用 |
| USD982434S1 (en) * | 2021-08-31 | 2023-04-04 | Level Up Dice LLC | Dice storage container |
| CN118119619A (zh) * | 2021-10-18 | 2024-05-31 | 上海美悦生物科技发展有限公司 | Sik抑制剂及其组合物、制备方法和用途 |
| AR128279A1 (es) * | 2022-01-19 | 2024-04-10 | Hoffmann La Roche | Nuevos derivados de bencimidazol piridina |
| CN115304605B (zh) * | 2022-01-21 | 2023-10-03 | 陕西国际商贸学院 | 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用 |
| WO2024003209A1 (fr) * | 2022-07-01 | 2024-01-04 | F. Hoffmann-La Roche Ag | Dérivés d'imidazo [4,5-c] pyridine en tant que modulateurs de sik pour le traitement de la polyarthrite rhumatoïde |
| US20240124450A1 (en) * | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
| CN120239700A (zh) * | 2022-11-17 | 2025-07-01 | 英矽智能科技知识产权有限公司 | 盐诱导激酶(sik)抑制剂及其使用方法 |
| EP4737443A1 (fr) | 2023-05-24 | 2026-05-06 | Tanabe Pharma Corporation | Composé inhibiteur de kinase inductible par un sel et composition pharmaceutique le contenant |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
| AR133277A1 (es) * | 2023-07-19 | 2025-09-10 | Hoffmann La Roche | Nuevos derivados de bencimidazol piridina |
| WO2025068090A1 (fr) * | 2023-09-26 | 2025-04-03 | Galapagos Nv | Composés et compositions pharmaceutiques de ceux-ci pour traiter des maladies |
| WO2025232877A1 (fr) * | 2024-05-10 | 2025-11-13 | Insilico Medicine Ip Limited | Inhibiteurs de kinases inductibles au sel (sik) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008279759A1 (en) * | 2007-07-20 | 2009-01-29 | Merck & Co., Inc. | Pyrazolo[1,5-a]pyrimidine derivatives |
| CN103282034A (zh) * | 2010-11-18 | 2013-09-04 | 利亘制药公司 | 造血生长因子模拟物的用途 |
| WO2012075252A1 (fr) * | 2010-12-01 | 2012-06-07 | Plasan Carbon Composites, Inc. | Procédé et système permettant de former des articles composites |
| WO2013135612A1 (fr) | 2012-03-14 | 2013-09-19 | Bayer Intellectual Property Gmbh | Imidazopyridazines substituées |
| US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| US10730842B2 (en) * | 2015-09-03 | 2020-08-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| CN106496222A (zh) * | 2016-09-07 | 2017-03-15 | 华东师范大学 | 一种咪唑并[1,2‑a]吡啶化合物及其制备方法和应用 |
| EP3717471B1 (fr) * | 2017-12-02 | 2022-01-05 | Galapagos NV | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies |
| CN108358894B (zh) * | 2018-04-26 | 2021-05-07 | 四川大学 | 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用 |
| MA52873A (fr) * | 2018-06-15 | 2021-04-21 | Galapagos Nv | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies |
| CN118684661A (zh) | 2023-03-21 | 2024-09-24 | 上海美悦生物科技发展有限公司 | 杂芳基类化合物及其药物组合物、制备方法和用途 |
-
2019
- 2019-05-29 GB GBGB1907616.5A patent/GB201907616D0/en not_active Ceased
-
2020
- 2020-05-25 US US17/614,854 patent/US12391679B2/en active Active
- 2020-05-25 ES ES20728465T patent/ES2985528T3/es active Active
- 2020-05-25 IL IL288375A patent/IL288375B2/en unknown
- 2020-05-25 PE PE2021001955A patent/PE20220503A1/es unknown
- 2020-05-25 CA CA3141683A patent/CA3141683A1/fr active Pending
- 2020-05-25 JP JP2021570425A patent/JP7550174B2/ja active Active
- 2020-05-25 AU AU2020281650A patent/AU2020281650B2/en active Active
- 2020-05-25 MA MA056019A patent/MA56019A/fr unknown
- 2020-05-25 WO PCT/EP2020/064368 patent/WO2020239658A1/fr not_active Ceased
- 2020-05-25 CN CN202080039185.0A patent/CN113924146B/zh active Active
- 2020-05-25 PL PL20728465.4T patent/PL3976189T3/pl unknown
- 2020-05-25 SG SG11202112652RA patent/SG11202112652RA/en unknown
- 2020-05-25 CR CR20210586A patent/CR20210586A/es unknown
- 2020-05-25 EP EP20728465.4A patent/EP3976189B1/fr active Active
- 2020-05-25 BR BR112021023900A patent/BR112021023900A2/pt unknown
- 2020-05-25 MX MX2021013803A patent/MX2021013803A/es unknown
- 2020-05-25 PH PH1/2021/552691A patent/PH12021552691A1/en unknown
- 2020-05-25 EA EA202193281A patent/EA202193281A1/ru unknown
- 2020-05-28 AR ARP200101505A patent/AR119028A1/es not_active Application Discontinuation
- 2020-05-28 TW TW109117844A patent/TW202110839A/zh unknown
-
2021
- 2021-11-03 DO DO2021000227A patent/DOP2021000227A/es unknown
- 2021-11-24 CL CL2021003133A patent/CL2021003133A1/es unknown
- 2021-12-17 ZA ZA2021/10597A patent/ZA202110597B/en unknown
- 2021-12-22 CO CONC2021/0017656A patent/CO2021017656A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA51739A (fr) | Compositions pharmaceutiques pour le traitement de la fibrose kystique | |
| MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
| MA50391A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires | |
| EP3866781A4 (fr) | Nouvelles compositions pour le traitement de maladies inflammatoires | |
| EP4045037C0 (fr) | Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1 | |
| EP3890747A4 (fr) | Compositions pour le traitement de la fibrose et de l'inflammation | |
| EP3908374A4 (fr) | Compositions et méthodes pour le diagnostic et le traitement de maladies neurodégénératives | |
| MA52118A (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| EP3937932A4 (fr) | Inhibiteurs de cgaz pour le traitement de maladies auto-inflammatoires et de métastases cancéreuses | |
| EP3934646A4 (fr) | Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires | |
| EP4045036A4 (fr) | Amides hétéroaryle-biphényle pour le traitement de maladies associées à pd-l1 | |
| EP3621973A4 (fr) | Composés pour la prévention et le traitement de maladies et leur utilisation | |
| EP3829569A4 (fr) | Formulations de spinosyne pour le traitement de maladies oculaires et faciaux provoquées par demodex | |
| EP3841086A4 (fr) | Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément | |
| EP3846830A4 (fr) | Méthodes et compositions pour le traitement de maladie musculo-squelettiques | |
| EP3661553A4 (fr) | Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes | |
| MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
| EP3639833A4 (fr) | Agent pour la prévention ou le traitement de maladies liées à la graisse et/ou de l'inflammation | |
| EP3877383A4 (fr) | Composés et compositions pour le traitement de maladies respiratoires | |
| EP3672587A4 (fr) | Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques | |
| EP3960858A4 (fr) | Petit médicament à base d'arn pour la prévention et le traitement de maladies liées à une l'inflammation et leur combinaison |